Congenital heart anomalies refer to structural defects in the heart that are present at birth. These anomalies occur during the early stages of fetal development when the heart is forming. While the exact causes of congenital heart anomalies are often unknown, genetic factors, environmental influences, and certain maternal conditions may contribute to their development. These anomalies can affect the heart's chambers, valves, or blood vessels, disrupting the normal flow of blood and leading to various complications. Common congenital heart anomalies include atrial septal defects, ventricular septal defects, and tetralogy of Fallot. The severity of these anomalies varies, with some cases causing minor issues that may not require intervention, while others may necessitate surgical correction. Advances in medical technology and surgical techniques have significantly improved the prognosis for individuals with congenital heart anomalies, allowing for early detection, timely intervention, and better long-term outcomes. Regular medical monitoring and appropriate medical care are crucial for managing these conditions throughout a person's life.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India